Mammalian model hosts of cryptococcal infection

Comparative Medicine

Volumn 57, Issue 1, 2007, Pages 9-17

  Carroll, Scott F ^a   Guillot, Loïc ^a   Qureshi, Salman T ^a  

^a MCGILL UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; CORTICOSTEROID; CORTISONE; CYCLOSPORIN A; FLUCONAZOLE; FLUCYTOSINE; INTERLEUKIN 12; INTERLEUKIN 2; ITRACONAZOLE; TRANSFORMING GROWTH FACTOR BETA1;

CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DISEASE MODEL; DRUG EFFICACY; EXPERIMENTAL GUINEA PIG; EXPERIMENTAL MOUSE; EXPERIMENTAL RABBIT; EXPERIMENTAL RAT; FUNGAL STRAIN; FUNGAL VIRULENCE; HOST PARASITE INTERACTION; HUMAN; IMMUNOPATHOGENESIS; IMMUNOSUPPRESSIVE TREATMENT; NONHUMAN; REVIEW; STRAIN DIFFERENCE; VACCINATION;

ANIMALS; CRYPTOCOCCOSIS; CRYPTOCOCCUS NEOFORMANS; DISEASE MODELS, ANIMAL; GUINEA PIGS; MICE; RABBITS; RATS; VIRULENCE FACTORS;

EID: 33847318749     PISSN: 15320820     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (126)

1. Aguirre K, Havell EA, Gibson GW, Johnson LL. 1995. Role of tumor necrosis factor and gamma interferon in acquired resistance to Cryptococcus neoformans in the central nervous system of mice. Infect Immun 63:1725-1731.
2. Anderson DA, Sagha HM. 1988. Persistence of infection in mice inoculated intranasally with Cryptococcus neoformans. Mycopathologia 104:163-169.
3. Arrese JE, Delvenne P, Van Cutsem J, Pierard-Franchimont C, Pierard GE. 1994. Experimental aspergillosis in guinea pigs: influence of itraconazole on fungaemia and invasive fungal growth. Mycoses 37:117-122.
4. Balasubramanian V, Wiegeshaus EH, Smith DW. 1994. Mycobacterial infection in guinea pigs. Immunobiology 191:395-401.
5. Beck JA, Lloyd S, Hafezparast M, Lennon-Pierce M, Eppig JT, Festing MF, Fisher EM. 2000. Genealogies of mouse inbred strains. Nat Genet 24:23-25.
6. Bergman F. 1966. Effect of temperature on intratesticular cryptococcal infection in rabbits. Sabouraudia 5:54-58.
7. Bicanic T, Harrison TS. 2005. Cryptococcal meningitis. Br Med Bull 72:99-118.
8. Blackstock R, Murphy JW. 2004. Age-related resistance of C57BL/6 mice to Cryptococcus neoformans is dependent on maturation of NKT cells. Infect Immun 72:5175-180.
9. Blasi E, Barluzzi R, Mazzolla R, Mosci P, Bistoni F. 1992. Experimental model of intracerebral infection with Cryptococcus neoformans: roles of phagocytes and opsonization. Infect Immun 60:3682-3688.
10. Blunt T, Gell D, Fox M, Taccioli GE, Lehmann AR, Jackson SP, Jeggo PA. 1996. Identification of a nonsense mutation in the carboxyl-terminal region of DNA-dependent protein kinase catalytic subunit in the SCID mouse. Proc Natl Acad Sci U S A 93:10285-10290.
11. Bogue MA, Grubb SC. 2004. The mouse phenome project. Genetica 122:71-74.
12. Bonner MJ, Medway W, Mitruka BM, Rawnsley HM, Vadehra DV. 1976. Animals for medical research. New York: John Wiley & Sons, Inc. p 29-31.
13. Broad Institute [Internet]. Mammalian Genome Project. [cited 21 Dec 2006]. Available at http://www.broad.mit.edu/mammals/.
14. Buer J, Balling R. 2003. Mice, microbes and models of infection. Nat Rev Genet 4:195-205.
15. Bulmer GS, Tacker JR. 1975. Phagocytosis of Cryptococcus neoformans by alveolar macrophages. Infect Immun 11:73-79.
16. Buschman E, Skamene E. 1999. Analysis of genetic susceptibility to infection in mice. In: Zak O, Sande MA, editors. Handbook of animal models of infection. London: Academic Press, Inc. p 75-81.
17. Casadevall A. 2005. Host as the variable: Model hosts approach the immunological asymptote. Infect Immun 73:3829-3832.
18. Casadevall A, Mukherjee J, Yuan R, Perfect J. 1994. Management of injuries caused by Cryptococcus neoformans contaminated needles. Clin Infect Dis 19:951-963.
19. Casadevall A, Perfect JR. 1998. Cryptococcus neoformans. Washington: ASM Press, Inc. p 19-438
20. Cauley LK, Murphy JW. 1979. Response of congenially athymic (nude) and phenotypically normal mice to Cryptococcus neoformans infection. Infect Immun 23:644-651.
21. Chang YC, Kwon-Chung KJ. 1994. Complementation of a capsule-deficient mutation of Cryptococcus neoformans restores its virulence. Mol Cell Biol 14:4912-4919.
22. Charlier C, Chretien F, Baudrimont M, Mordelet E, Lortholary O, Dromer F. 2005. Capsule structure changes associated with Cryptococcus neoformans crossing of the blood-brain barrier. Am J Pathol 166:421-432.
23. Chaturvedi V, Wong B, Newman SL. 1996. Oxidative killing of Cryptococcus neoformans by human neutrophils. Evidence that fungal mannitol protects by scavenging reactive oxygen intermediates. J Immunol 156:3836-3840.
24. Chen LC, Blank ES, Casadevall A. 1996. Extracellular proteinase activity of Cryptococcus neoformans. Clin Diagn Lab Immunol 3:570-574.
25. Chia R, Achilli F, Festing MF, Fisher EM. 2005. The origins and uses of mouse outbred stocks. Nat Genet 37:1181-1186.
26. Chretien F, Lortholary O, Kansau I, Neuville S, Gray F, Dromer F. 2002. Pathogenesis of cerebral Cryptococcus neoformans infection after fungemia. J Infect Dis 186:522-530.
27. Cohen ML. 2000. Changing patterns of infectious disease. Nature 406:762-767.
28. Cox GM, McDade HC, Chen SC, Tucker SC, Gottfredsson M, Wright LC, Sorrell TC, Leidich SD, Casadevall A, Ghannoum MA, Perfect JR. 2001. Extracellular phospholipase activity is a virulence factor for Cryptococcus neoformans. Mol Microbiol 39:166-175.
29. Cox GM, Mukherjee J, Cole GT, Casadevall A, Perfect JR. 2000. Urease as a virulence factor in experimental cryptococcosis. Infect Immun 68:443-448.
30. Decken K, Kohler G, Palmer-Lehmann K, Wunderlin A, Mattner F, Magram J, Gately MK, Alber G. 1998. Interleukin-12 is essential for a protective Th1 response in mice infected with Cryptococcus neoformans. Infect Immun 66:4994-5000.
31. Diamond RD. 1977. Effects of stimulation and suppression of cell-mediated immunity on experimental cryptococcosis. Infect Immun 17:187-194.
32. Dixon DM, McNeil MM, Cohen ML, Gellin BG, La Montagne JR. 1996. Fungal infections: a growing threat. Public Health Rep 111:226-235.
33. Doyle HA, Murphy JW. 1997. MIP-1 alpha contributes to the anti-cryptococcal delayed-type hypersensitivity reaction and protection against Cryptococcus neoformans. J Leukoc Biol 61:147-155.
34. Escandon P, Sanchez A, Martinez M, Meyer W, Castaneda E. 2006. Molecular epidemiology of clinical and environmental isolates of the Cryptococcus neoformans species complex reveals a high genetic diversity and the presence of the molecular type VGII mating type a in Colombia. FEMS Yeast Res 6:625-635.
35. Fan W, Kraus PR, Boily MJ, Heitman J. 2005. Cryptococcus neoformans gene expression during murine macrophage infection. Eukaryot Cell 4:1420-1433.
36. Festing MFW. 1979. Inbred strains in biomedical research. New York: Oxford University Press, Inc. p xii-483.
37. Friedman GD. 1983. The rarity of cryptococcosis in northern california: The 10-year experience of a large defined population. Am J Epidemiol 117:230-234.
38. Fujita NK, Hukkanen J, Edwards JE, Jr. 1983. Experimental hematogenous endophthalmitis due to Cryptococcus neoformans. Invest Ophthalmol Vis Sci 24:368-375.
39. Gadebusch HH, Gikas PW. 1965. The effect of cortisone upon experimental pulmonary cryptococcosis. Am. Rev. Respir. Dis. 92:64-74.
40. Goldman D, Cho Y, Zhao M, Casadevall A, Lee SC 1996. Expression of inducible nitric oxide synthase in rat pulmonary Cryptococcus neoformans granulomas. Am J Pathol 148:1275-1282.
41. Goldman D, Lee SC, Casadevall A. 1994. Pathogenesis of pulmonary Cryptococcus neoformans infection in the rat. Infect Immun 62:4755-4761.
42. Goldman DL, Casadevall A. 1999. Experimental pulmonary Cryptococcus neoformans infection in rats. In: Zak O, Sande MA, editors. Handbook of animal models of infection. London: Academic Press, Inc. p 687-692.
43. Goldman DL, Casadevall A, Cho Y, Lee SC. 1996. Cryptococcus neoformans meningitis in the rat. Lab Invest 75:759-770.
44. Goldman DL, Khine H, Abadi J, Lindenberg DJ, Pirofski L, Niang R, Casadevall A. 2001. Serologic evidence for Cryptococcus neoformans infection in early childhood. Pediatrics 107:E66.
45. Goldman DL, Lee SC, Mednick AJ, Montella L, Casadevall A. 2000. Persistent Cryptococcus neoformans pulmonary infection in the rat is associated with intracellular parasitism, decreased inducible nitric oxide synthase expression, and altered antibody responsiveness to cryptococcal polysaccharide. Infect Immun 68:832-838.
46. Graybill JR, Ahrens J, Nealon T, Paque R. 1983. Pulmonary cryptococcosis in the rat. Am Rev Respir Dis 127:636-640.
47. Hage CA, Wood KL, Winer-Muram HT, Wilson SJ, Sarosi G, Knox KS. 2003. Pulmonary cryptococcosis after initiation of anti-tumor necrosis factor-alpha therapy. Chest 124:2395-2397.
48. Hakim JG, Gangaidzo IT, Heyderman RS, Mielke J, Mushangi E, Taziwa A, Robertson VJ, Musvaire P, Mason PR. 2000. Impact of hiv infection on meningitis in Harare, Zimbabwe: A prospective study of 406 predominantly adult patients. AIDS 14:1401-1407.
49. Hamilton JD, Elliott DM. 1975. Combined activity of amphotericin B and 5-fluorocytosine against Cryptococcus neoformans in vitro and in vivo in mice. J Infect Dis 131:129-137.
50. He W, Casadevall A, Lee SC, Goldman DL. 2003. Phagocytic activity and monocyte chemotactic protein expression by pulmonary macrophages in persistent pulmonary cryptococcosis. Infect Immun 71:930-936.
51. Huffnagle GB, Boyd MB, Street NE, Lipscomb MF. 1998. II-5 is required for eosinophil recruitment, crystal deposition, and mononuclear cell recruitment during a pulmonary Cryptococcus neoformans infection in genetically susceptible mice (C57BL/6). J Immunol 160:2393-2400.
52. Huffnagle GB, Deepe GS. 2003. Innate and adaptive determinants of host susceptibility to medically important fungi. Curr Opin Microbiol 6:344-350.
53. Huffnagle GB, Strieter RM, Standiford TJ, McDonald RA, Burdick MD, Kunkel SL, Toews GB. 1995. The role of monocyte chemotactic protein-1 (MCP-1) in the recruitment of monocytes and CD4+ t cells during a pulmonary Cryptococcus neoformans infection. J Immunol 155:4790-4797.
54. Huffnagle GB, Toews GB, Burdick MD, Boyd MB, McAllister KS, McDonald RA, Kunkel SL, Strieter RM. 1996. Afferent phase production of TNF-alpha is required for the development of protective t cell immunity to Cryptococcus neoformans. J Immunol 157:4529-4536.
55. Huffnagle GB, Yates JL, Lipscomb MF. 1991. T cell-mediated immunity in the lung: A Cryptococcus neoformans pulmonary infection model using SCID and athymic nude mice. Infect Immun 59:1423-1433.
56. Husain S, Wagener MM, Singh N. 2001. Cryptococcus neoformans infection in organ transplant recipients: Variables influencing clinical characteristics and outcome. Emerg Infect Dis 7:375-381.
57. Idnurm A, Bahn YS, Nielsen K, Lin X, Fraser JA, Heitman J. 2005. Deciphering the model pathogenic fungus Cryptococcus neoformans. Nat Rev Microbiol 3:753-764.
58. Iseki M, Anzo M, Yamashita N, Matsuo N. 1994. Hyper-IgM immunodeficiency with disseminated cryptococcosis. Acta Paediatr 83:780-782.
59. Kartalija M, Kaye K, Tureen JH, Liu Q, Tauber MG, Elliott BR, Sande MA. 1996. Treatment of experimental cryptococcal meningitis with fluconazole: Impact of dose and addition of flucytosine on mycologic and pathophysiologic outcome. J Infect Dis 173:1216-1221.
60. Kawakami K, Koguchi Y, Qureshi MH, Kinjo Y, Yara S, Miyazato A, Kurimoto M, Takeda K, Akira S, Saito A. 2000. Reduced host resistance and Th1 response to Cryptococcus neoformans in interleukin-18 deficient mice. FEMS Microbiol Lett 186:121-126.
61. Kawakami K, Tohyama M, Teruya K, Kudeken N, Xie Q, Saito A. 1996. Contribution of interferon-gamma in protecting mice during pulmonary and disseminated infection with Cryptococcus neoformans. FEMS Immunol Med Microbiol 13:123-130.
62. Kobayashi M, Ito M, Sano K, Koyama M. 2001. Granulomatous and cytokine responses to pulmonary Cryptococcus neoformans in two strains of rats. Mycopathologia 151:121-130.
63. Koguchi Y, Kawakami K. 2002. Cryptococcal infection and Th1-Th2 cytokine balance. Int Rev Immunol 21:423-438.
64. Kwon-Chung KJ, Polacheck I, Popkin TJ. 1982. Melanin-lacking mutants of Cryptococcus neoformans and their virulence for mice. J Bacteriol 150:1414-1421.
65. Kwon-Chung KJ, Varma A. 2006. Do major species concepts support one, two or more species within Cryptococcus neoformans? FEMS Yeast Res 6:574-587.
66. Larsen RA, Bauer M, Thomas AM, Graybill JR. 2004. Amphotericin B and fluconazole, a potent combination therapy for cryptococcal meningitis. Antimicrob Agents Chemother 48:985-991.
67. Larsen RA, Bauer M, Weiner JM, Diamond DM, Leal ME, Ding JC, Rinaldi MG, Graybill JR. 1996. Effect of fluconazole on fungicidal activity of flucytosine in murine cryptococcal meningitis. Antimicrob Agents Chemother 40:2178-2182.
68. Larsen RA, Pappas PG, Perfect J, Aberg JA, Casadevall A, Cloud GA, James R, Filler S, Dismukes WE. 2005. Phase I evaluation of the safety and pharmacokinetics of murine-derived anticryptococcal antibody 18B7in subjects with treated cryptococcal meningitis. Antimicrob Agents Chemother 49:952-958.
69. Lazar J, Moreno C, Jacob HJ, Kwitek AE. 2005. Impact of genomics on research in the rat. Genome Res 15:1717-1728.
70. Levitz SM. 1991. Activation of human peripheral blood mononuclear cells by interleukin-2 and granulocyte-macrophage colony-stimulating factor to inhibit Cryptococcus neoformans. Infect Immun 59:3393-3397.
71. Levitz SM, DiBenedetto DJ. 1989. Paradoxical role of capsule in murine bronchoalveolar macrophage-mediated killing of Cryptococcus neoformans. J Immunol 142:659-665.
72. Li MO, Wan YY, Sanjabi S, Robertson AK, Flavell RA. 2006. Transforming growth factor-beta regulation of immune responses. Annu Rev Immunol 24:99-146.
73. Lima C, Vital JP. 1994. Olfactory mucosa response in guinea pigs following intranasal instillation with Cryptococcus neoformans. A histological and immunocytochemical study. Mycopathologia 126:65-73.
74. Lin X, Heitman J. 2006. The biology of the Cryptococcus neoformans species complex. Annu Rev Microbiol 60:69-105.
75. Lipscomb MF, Lyons CR, Izzo AA, Lovchik J, Wilder JA. 1999. Experimental pulmonary cryptococcal infection in mice. In: Zak O, Sande MA, editors. Handbook of animal models of infection. London: Academic Press, Inc. p 681-686.
76. London R, Orozco BS, Mylonakis E. 2006. The pursuit of cryptococcal pathogenesis: heterologous hosts and the study of cryptococcal host-pathogen interactions. FEMS Yeast Res 6:567-573.
77. Louria DB, Fallon N, Browne HG. 1960. The influence of cortisone on experimental fungus infections in mice. J Clin Invest 39:1435-1449.
78. Lovchik JA, Wilder JA, Huffnagle GB, Riblet R, Lyons CR, Lipscomb MF. 1999. Ig heavy chain complex-linked genes influence the immune response in a murine cryptococcal infection. J Immunol 163:3907-3913.
79. Lui G, Lee N, Ip M, Choi KW, Tso YK, Lam E, Chau S, Lai R, Cockram CS. 2006. Cryptococcosis in apparently immunocompetent patients. Qjm 99:143-151.
80. Maebashi K, Itoyama T, Uchida K, Suegara N, Yamaguchi H. 1994. A novel model of cutaneous candidiasis produced in prednisolone-treated guinea-pigs. J Med Vet Mycol 32:349-359.
81. Marquis G, Montplaisir S, Pelletier M, Mousseau S, Auger P. 1985. Genetic resistance to murine cryptococcosis: the beige mutation (Chediak-Higashi syndrome) in mice. Infect Immun 47:288293.
82. Marquis G, Montplaisir S, Pelletier M, Mousseau S, Auger P. 1985. Genetic resistance to murine cryptococcosis: Increased susceptibility in the CBA/N XID mutant strain of mice. Infect Immun 47:282-287.
83. Martinez LR, Moussai D, Casadevall A. 2004. Antibody to Cryptococcus neoformans glucuronoxylomannan inhibits the release of capsular antigen. Infect Immun 72:3674-3679.
84. Mashimo T, Voigt B, Kuramoto T, Serikawa T. 2005. Rat phenome project: The untapped potential of existing rat strains. J Appl Physiol 98:371-379.
85. McClelland EE, Adler FR, Granger DL, Potts WK. 2004. Major histocompatibility complex controls the trajectory but not host-specific adaptation during virulence evolution of the pathogenic fungus Cryptococcus neoformans. Proc Biol Sci 271:1557-1564.
86. Mestas J, Hughes CC. 2004. Of mice and not men: differences between mouse and human immunology. J Immunol 172:2731-2738.
87. Meyer W, Castaneda A, Jackson S, Huynh M, Castaneda E. 2003. Molecular typing of iberoamerican Cryptococcus neoformans isolates. Emerg Infect Dis 9:189-195.
88. Meyer W, Marszewska K, Amirmostofian M, Igreja RP, Hardtke C, Methling K, Viviani MA, Chindamporn A, Sukroongreung S, John MA, Ellis DH, Sorrell TC. 1999. Molecular typing of global isolates of Cryptococcus neoformans var. neoformans by polymerase chain reaction fingerprinting and randomly amplified polymorphic DNA-a pilot study to standardize techniques on which to base a detailed epidemiological survey. Electrophoresis 20:1790-1799.
89. Mitchell TG, Perfect JR. 1995. Cryptococcosis in the era of AIDS-100 years after the discovery of Cryptococcus neoformans. Clin Microbiol Rev 8:515-548.
90. Murphy JW. 1998. Protective cell-mediated immunity against Cryptococcus neoformans. Res Immunol 149:373-386.
91. Nadrous HF, Antonios VS, Terrell CL, Ryu JH. 2003. Pulmonary cryptococcosis in nonimmunocompromised patients. Chest 124:2143-2147.
92. Nessa K, Gross NT, Jarstrand C, Johansson A, Camner P. 1997. In vivo interaction between alveolar macrophages and Cryptococcus neoformans. Mycopathologia 139:1-7.
93. Nguyen MH, Najvar LK, Yu CY, Graybill JR. 1997. Combination therapy with fluconazole and flucytosine in the murine model of cryptococcal meningitis. Antimicrob Agents Chemother 41:1120-1123.
94. Nosanchuk JD, Mednick A, Shi L, Casadevall A. 2003. Experimental murine cryptococcal infection results in contamination of bedding with Cryptococcus neoformans. Contemp Top Lab Anim Sci 42(4):9-12.
95. Odds FC, Oris M, Van Dorsselaer P, Van Gerven F. 2000. Activities of an intravenous formulation of itraconazole in experimental disseminated aspergillus, Candida, and cryptococcus infections. Antimicrob Agents Chemother 44:3180-3183.
96. Odom A, Muir S, Lim E, Toffaletti DL, Perfect J, Heitman J. 1997. Calcineurin is required for virulence of Cryptococcus neoformans. Embo J 16:2576-2589.
97. Patterson TF, Miniter P, Dijkstra J, Szoka FC, Jr., Ryan JL, Andriole VT. 1989. Treatment of experimental invasive aspergillosis with novel amphotericin B/cholesterol-sulfate complexes. J Infect Dis 159:717-724.
98. Perfect JR. 2005. Cryptococcus neoformans: A sugar-coated killer with designer genes. FEMS Immunol Med Microbiol 45:395-404.
99. Perfect JR. 1999. Rabbit model of cryptococcal meningitis. In: Zak O, Sande MA, editors. Handbook of animal models of infection. London: Academic Press, Inc. p 721-776.
100. Perfect JR, Casadevall A. 2002. Cryptococcosis. Infect Dis Clin North Am 16:837-874, v-vi.
101. Perfect JR, Durack DT. 1985. Effects of cyclosporine in experimental cryptococcal meningitis. Infect Immun 50:22-26.
102. Perfect JR, Durack DT. 1985. Comparison of amphotericin B and N-D-ornithyl amphotericin B methyl ester in experimental cryptococcal meningitis and candida albicans endocarditis with pyelonephritis. Antimicrob Agents Chemother 28:751-755.
103. Perfect JR, Durack DT. 1982. Treatment of experimental cryptococcal meningitis with amphotericin B, 5-fluorocytosine, and ketoconazole. J Infect Dis 146:429-435.
104. Perfect JR, Lang SD, Durack DT. 1980. Chronic cryptococcal meningitis: a new experimental model in rabbits. Am J Pathol 101:177-194.
105. Perfect JR, Wright KA. 1994. Amphotericin B lipid complex in the treatment of experimental cryptococcal meningitis and disseminated candidosis. J Antimicrob Chemother 33:73-81.
106. Petraitiene R, Petraitis V, Groll AH, Candelario M, Sein T, Bell A, Lyman CA, McMillian CL, Bacher J, Walsh TJ. 1999. Antifungal activity of ly303366, a novel echinocandin b, in experimental disseminated candidiasis in rabbits. Antimicrob Agents Chemother 43:2148-2155.
107. Polak A, Scholer HJ, Wall M. 1982. Combination therapy of experimental candidiasis, cryptococcosis and aspergillosis in mice. Chemotherapy 28:461-479.
108. Randhawa HS, Mussa AY, Khan ZU. 2001. Decaying wood in tree trunk hollows as a natural substrate for Cryptococcus neoformans and other yeast-like fungi of clinical interest. Mycopathologia 151:63-69.
109. Rhodes JC. 1985. Contribution of complement component C5 to the pathogenesis of experimental murine cryptococcosis. Sabouraudia 23:225-234.
110. Rhodes JC, Wicker LS, Urba WJ. 1980. Genetic control of susceptibility to Cryptococcus neoformans in mice. Infect Immun 29:494-499.
111. Richmond J, McKinney R. 1999. Biosafety in microbiological and biomedical laboratories. Washington: US Government Printing Office. p 120-121.
112. Riera CM, Masih DT, Nobile R. 1983. Experimental cryptococcosis in guinea pigs. Mycopathologia 82:179-184.
113. Saoudi A, Bernard I, Hoedemaekers A, Cautain B, Martinez K, Druet P, De Baets M, Guery JC. 1999. Experimental autoimmune myasthenia gravis may occur in the context of a polarized Th1- or Th2-type immune response in rats. J Immunol 162:7189-7197.
114. Segre JA, Nemhauser JL, Taylor BA, Nadeau JH, Lander ES. 1995. Positional cloning of the nude locus: Genetic, physical, and transcription maps of the region and mutations in the mouse and rat. Genomics 28:549-559.
115. Shao X, Mednick A, Alvarez M, van Rooijen N, Casadevall A, Goldman DL. 2005. An innate immune system cell is a major determinant of species-related susceptibility differences to fungal pneumonia. J Immunol 175:3244-3251.
116. Shao X, Rivera J, Niang R, Casadevall A, Goldman DL. 2005. A dual role for TGF-beta1 in the control and persistence of fungal pneumonia. J Immunol 175:6757-6763.
117. Steenbergen JN, Shuman HA, Casadevall A. 2001. Cryptococcus neoformans interactions with amoebae suggest an explanation for its virulence and intracellular pathogenic strategy in macrophages. Proc Natl Acad Sci U S A 98:15245-15250.
118. Sukroongreung S, Kitiniyom K, Nilakul C, Tantimavanich S. 1998. Pathogenicity of basidiospores of Filobasidiella neoformans var. neoformans. Med Mycol 36:419-424.
119. Sweeney DA, Caserta MT, Korones DN, Casadevall A, Goldman DL. 2003. A ten-year-old boy with a pulmonary nodule secondary to Cryptococcus neoformans: Case report and review of the literature. Pediatr Infect Dis J 22:1089-1093.
120. Tabone MD, Leverger G, Landman J, Aznar C, Boccon-Gibod L, Lasfargues G. 1994. Disseminated lymphonodular cryptococcosis in a child with X-linked hyper-IgM immunodeficiency. Pediatr Infect Dis J 13:77-79.
121. Traynor TR, Herring AC, Dorf ME, Kuziel WA, Toews GB, Huffnagle GB. 2002. Differential roles of CC chemokine ligand 2/monocyte chemotactic protein-1 and CCR2 in the development of T1 immunity. J Immunol 168:4659-4666.
122. Van Cutsem J, Fransen J, Janssen PA. 1988. Experimental zygomycosis due to rhizopus spp. Infection by various routes in guinea-pigs, rats and mice. Mycoses 31:563-578.
123. Vecchiarelli A, Casadevall A. 1998. Antibody-mediated effects against Cryptococcus neoformans: evidence for interdependency and collaboration between humoral and cellular immunity. Res Immunol 149:321-33; discussion 500-503.
124. Vecchiarelli A, Retini C, Casadevall A, Monari C, Pietrella D, Kozel TR. 1998. Involvement of C3a and C5a in interleukin-8 secretion by human polymorphonuclear cells in response to capsular material of Cryptococcus neoformans. Infect Immun 66:4324-4330.
125. Wang Y, Aisen P, Casadevall A. 1995. Cryptococcus neoformans melanin and virulence: mechanism of action. Infect Immun 63:3131-3136.
126. Zaragoza O, Casadevall A. 2004. Experimental modulation of capsule size in Cryptococcus neoformans. Biol Proced Online 6:10-15.